Liquidia Corporation Common Stock LQDA
Analyst Ratings
- Consensus
- Hold — 4 Buy · 4 Hold · 1 Sell (9 analysts)
- Avg. Price Target
- $58.63 (+118.7% upside)
Key Stats
- Today's Range
- $26.13 – $27.40
- 50-Day Range
- $22.31 – $93.61
- 52-Week Range
- $21.14 – $93.61
- Volume
- 7.65 million shs
- Average Volume
- 3.96 million shs
- Market Cap
- $2.48 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.00%
- Days to Cover
- 1.00
About Liquidia Corporation Common Stock
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Related Stocks
Compare head-to-head: LQDA vs LLY·LQDA vs JNJ·LQDA vs ABBV·LQDA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.